Announcements
- Matinas BioPharma Prices $10 Million Registered Direct Offering
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
- Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
- Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
- Matinas BioPharma to Present at Biotech Showcase 2024
- Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
- Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
More ▼
Key statistics
On Friday, Matinas BioPharma Holdings Inc (6LJ:DUS) closed at 0.1648, 58.46% above the 52 week low of 0.104 set on Oct 04, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1388 |
---|---|
High | 0.1748 |
Low | 0.1388 |
Bid | 0.1647 |
Offer | 0.1725 |
Previous close | 0.1646 |
Average volume | 7.40k |
---|---|
Shares outstanding | 250.82m |
Free float | 244.48m |
P/E (TTM) | -- |
Market cap | 44.87m USD |
EPS (TTM) | -0.1056 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 18:31 BST.
More ▼